Kopran Q2 Results 2026: PAT ₹4 Cr (turned profitable)
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹211Cr
- +79.2% YoY
- +37.2% QoQ
- Net profit
- ₹4Cr
- Turned profitable YoY
- −34.5% QoQ
- Margin
- 7.29%
- +11.8 pp YoY
- −3 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Kopran Ltd Q2 FY27 key numbers
- Revenue
- Revenue from Operations for Q2 FY 2026-27: Rs. 21,126 lakhs.
As stated in Kopran Ltd's Q2 FY27 investor presentation · published 3 Nov 2026. Reported figures, not investment advice.
Based on Kopran Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue from Operations for Q2 FY 2026-27: Rs. 21,126 lakhs (Page 5). EBITDA for Q2 2026-27: Rs. 1,822 Lakhs, up from Rs. 299 Lakhs in Q2 2025-26 (YoY increase).
From Kopran Ltd's Q2 FY27 earnings-call transcript · updated 3 Nov 2026.
How did Kopran's revenue grow in the September 2026 quarter?
What happened to Kopran's margins in Q2 FY27?
EBITDA for Q2 2026-27: Rs. 1,822 Lakhs, up from Rs. 299 Lakhs in Q2 2025-26 (YoY increase).
Locked: what Kopran Ltd said on margins
Also locked on this page: fundraising, order book
Free account, 30 seconds. No card needed.
What capex is Kopran planning?
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Kopran raising money or cutting debt?
Borrowings (Rs. in Lakhs) increased from 15,269 in FY 2025-26 to 20,837 in HY SEP-2026, indicating a rise…
Locked: what Kopran Ltd said on fundraising
Also locked on this page: margins, order book
Free account, 30 seconds. No card needed.
How big is Kopran's order book?
See what Kopran Ltd said on order book & pipeline — free account, 30 seconds.
Kopran Ltd — Quarterly revenue & net profit
Kopran Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 211 |
| Operating profit (EBITDA) | 15 |
| Operating margin | 7.3% |
| Profit before tax | 6 |
| Net profit (PAT) | 4 |
| EPS (₹) | 0.91 |
Source: Kopran Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹211 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
What Kopran's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Vineet Laborator (Q2 FY27)
Year-on-year change: Decrease of approximately INR 323.65 lakh or about 18.58% decline . Key results statement takeaways from Vineet Laboratories Ltd's Q2 FY27
- Balaxi Pharma (Q2 FY27)
34.1% increase (from Rs. Key results statement takeaways from Balaxi Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Alkem Lab (Q2 FY27)
Total Revenue from Operations in Q2 FY27: ₹45,520 million, up 13.8% YoY. Key investor presentation takeaways from Alkem Laboratories Ltd's Q2 FY27 investor pres
- Caplin Point Laboratories Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹629.84 crore, up 17.9% YoY (compared to ₹534.04 crore in Q2 FY26). Key investor presentation takeaways from Caplin Point Labor
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Kopran Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Kopran Ltd Q2 FY27 results?
Revenue from Operations for Q2 FY 2026-27: Rs. 21,126 lakhs (Page 5). EBITDA for Q2 2026-27: Rs. 1,822 Lakhs, up from Rs. 299 Lakhs in Q2 2025-26 (YoY increase).
What is Kopran Ltd share price analysis?
Kopran Ltd currently shows a neutral. The stock trades at a P/E of 46.8 with a market cap of ₹1,171 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kopran Ltd planning capital expenditure?
Focus on capacity expansion is highlighted as a strategic imperative (Page 15). - Emphasis on process improvements and atomization of packing lines in formulations without quantification (Page 15).
Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
